Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Antiamyloid Therapy for Alzheimers Disease - Are We on the Right Road?
NEJM 370:377-378, Karran, E. & Hardy, J., 2014
Memantine for Dementia in Adults Older than 40 years with Downs Syndrome (MEADOWS): a Randomised,double-blind,placebo-controlled Trial
Lancet 379:528-536, Hanney,M.,et al, 2012
Genetic Aspects of Alzheimer Disease
The Neurologist 15:80-86, Williamson,J.,et al, 2009
In Vivo Mapping of Amyloid Toxicity in Alzheimer Disease
Neurol 72:1504-1511, Frisoni,B.G.,et al, 2009
Long-Term Effects of the Concomitant Use of Memantine with Cholinesterase Inhibition in Alzheimer Disease
JNNP 80:600-607, Lopez,O.L.,et al, 2009
Risk of Dementia and AD with Prior Exposure to NSAIDs in an Elderly Community-Based Cohort
Neurol 72:1899-1905,1884, Breitner,J.C.S.,et al, 2009
NSAID Use and Dementia Risk in the Cardiovascular Health Study: Role of APOE and NSAID Type
Neurol 70:17-24, Szekely,C.A.,et al, 2008
Disease-Modifying Therapies for Alzheimers: New Drugs on the Horizon
Practical Neurology 7:16-23, Christensen,D.B., 2008
Phase 2 Safety Trial Targeting Amyloid � Production With a ?-Secretase Inhibitor in Alzheimer Disease
Arch Neurol 65:1031-1038, Fleisher,A.S.,et al., 2008
A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Arch Neurol 63:49-54, Reisberg,B.,et al, 2006
Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil, A Randomized Controlled Trial
JAMA 291:317-324, Tariot,P.N.,et al, 2004
Alzheimer's Disease
NEJM 351:56-67, Cummings,J.L, 2004
Memantine in Moderate-to-Severe Alzheimer's Disease
NEJM 348:1333-1341, Reisberg,B.,et al, 2003
Tolerability of Memantine in Combination with Cholinesterase Inhibitors in Dementia Therapy
Int Clin Psychopharm 18:81-85, Hartmann,S.& Mobius, H.J., 2003
Reduced Incidence of AD with NSAID But Not H2 Receptor Antagonists
Neurol 59:880-886, Zandi,P.P.,et al, 2002
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
NEJM 345:1515-1521,1567, in 'T Veld,B.A.,et al, 2001
Reduced Prevalence of AD in Users of NSAIDs and H2 Receptor Antagonists
Neurol 54:2066-2071, Anthony,J.C.,et al, 2000
Anti-Inflammatory Drugs Protect Against Alzheimer Disease at Low Doses
Arch Neurol 57:1586-1591, Broe,G.A.,et al, 2000
Treatment of Alzheimer's Disease
NEJM 341:1670-1679, Mayeux,R.&Sano,M, 1999
Pharmacologic Treatment of Cognition in Alzheimer's Dementia
Neurol 51:S36-S44, Farlow,M.R.&Evans,R.M., 1998
Nonsteroidal Anti-Inflammatory Drug use and Alzheimer-Type Pathology in Aging
Neurol 50:986-990, Mackenzie,I.&Munoz,D.G., 1998
The Clinical Introduction of Genetic Testing for Alzheimer Disease, An Ethical Perspective
JAMA 277:832-836, Post,S.G.,et al, 1997
Risk of Alzheimer's Disease and Duration of NSAID Use
Neurol 48:626-632, Stewart,W.F.,et al, 1997
Genetic Testing for Alzheimer Disease, Practical and Ethical Issues
Arch Neurol 54:1226-1229, Roses,A.D., 1997
Apolipoprotein E Genotyping in Alzheimer's Disease
Lancet 347:1091-1095, Tanzi,R.,et al, 1996
Arthritis & Anti-Inflammatory Agents as Possible Protective Factors for Alzheimer's Dis:Review of 17 Epidemiologic Studies
Neurol 47:425-432, McGeer,P.L.,et al, 1996
Genetic Factors in Alzheimer's Disease:A Review of Recent Advances
Ann Neurol 40:829-840, Levy-Lahad,E.&Bird,T.D., 1996
Do Nonsteroidal Anti-Inflammatory Drugs Decrease Risk for Alzheimer's Disease, Rotterdam Study
Neurol 45:1441-1445, Andersen,K.,et al, 1995
Apolipoprotein E Allele E4, Dementia, and Cognitive Decline in a Population Sample
Lancet 346:1387-1390, Henderson,A.S.,et al, 1995
Statement of Use of Apolipoprotein E Testing for Alzheimer Disease
JAMA 274:1627-1629, Farrer,L.A.,et al, 1995
Apoliprprotein E E4 Allele & the Lifetime Risk of Alzheimer's Disease:What Physicians Know, & What They Should Know
Arch Neurol 52:1074-1079, Seshadri,S.,et al, 1995
Apolipoprotein E Genotype in Patients with Alzheimer's Disease:Implications for Risk of Dementia Among Relatives
Ann Neurol 38:797-808, Farrer,L.A.,et al, 1995
Clinical Genetics and Genetic Counseling in Alzheimer Disease
Ann Int Med 115:601-606, Breitner,J.C.S., 1991